NNVC.US NanoViricides Inc

Healthcare Biotechnology USA Stocks
1.23 USD
Close of Nov 15, 2026
0.8500 1.93
Market cap
USD 31.4M
P/E
-
P/B
3.62x
ROE
-94.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is NNVC.US undervalued?

Graham number

The Graham number of NanoViricides Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NanoViricides Inc fundamental analysis

No fundamental analysis for NanoViricides Inc yet.

NanoViricides Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NanoViricides Inc

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup a…

Full company profile